Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Immunome Inc.IMNM · Entity 4219 | Chief Scientific Officer | September 11, 2026 | September 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Immunome Inc.
Report date September 11, 2026 · Filed September 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 56,250 |
Ending reported balance
After 2026-09-11 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-11 · Exercise / conversion · Acquired 18,000 · Balance 78,250 Row 2 · 2026-09-11 · Sale · Disposed 13,200 · Balance 65,050 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Row 3 · 2026-09-11 · Gift · Disposed 8,800 · Balance 56,250 |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.35 · Expires 2032-06-23 | Direct | 133,840 |
Reported balance
After 2026-09-11 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-09-11 · Exercise / conversion · Acquired 18,000 · Balance 133,840 F3: 25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. |
| Common StockSEC Table I · non-derivative | IndirectAs Custodian for Child 1 | 1,000 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 1,000 F2: The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectAs Custodian for Child 2 | 1,000 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 1,000 F2: The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectAs Custodian for Child 3 | 1,000 |
Reported balance
Holding disclosure · report date 2026-09-11 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 1,000 F2: The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025.
F2: The Reporting Person serves as a custodian of a custodial account for his child pursuant to the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose.
F3: 25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionEmployee Stock Option (right to buy) · Derivative | 18,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001993684-26-000008 · form4-09152026_040933.xml · derivative · entry 7 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,840 Underlying: Common Stock · 18,000 shares Expires 2032-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the options vested on May 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares subject to the options vests every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Immunome Inc. IMNM · Entity 4219 | GiftCommon Stock | 8,800 | $0.00 | $0.00 |
DisclosureSEC source: 0001993684-26-000008 · form4-09152026_040933.xml · nonDerivative · entry 3 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 56,250 Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 13,200 | $25.32 | $334,224.00 |
DisclosureSEC source: 0001993684-26-000008 · form4-09152026_040933.xml · nonDerivative · entry 2 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,050 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| September 11, 2026 Filed Sep 15, 2026 20:30 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 18,000 | $1.35 | $24,300.00 |
DisclosureSEC source: 0001993684-26-000008 · form4-09152026_040933.xml · nonDerivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,250 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 76,500 | $0.00 Strike: $22.01 | $0.00 |
DisclosureSEC source: 0001993684-26-000006 · form4-07272026_040707.xml · derivative · entry 5 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,500 Underlying: Common Stock · 76,500 shares Expires 2036-07-22 F3 · derivative.exercise_date: 25% of the shares subject to the options vest on July 23, 2027, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| July 23, 2026 Filed Jul 27, 2026 20:10 UTC | Immunome Inc. IMNM · Entity 4219 | GrantCommon Stock | 38,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001993684-26-000006 · form4-07272026_040707.xml · nonDerivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,250 F1 · shares: Represents the number of shares of the Issuer's common stock ("Common Stock") underlying restricted stock units ("RSUs"). Each RSU represents the contingent right to receive one share of Common Stock upon settlement. 25% of the RSUs will vest and settle into Common Stock annually on each anniversary of the grant date, subject to the Reporting Person's continuous service through each such vesting date. Read SEC document |
| April 02, 2026 Filed Apr 3, 2026 23:48 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 9,438 | $21.64 | $204,238.32 |
DisclosureSEC source: 0001993684-26-000004 · form4-04032026_110409.xml · nonDerivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 19, 2025. Read SEC document |
| March 30, 2026 Filed Apr 1, 2026 21:39 UTC | Immunome Inc. IMNM · Entity 4219 | GiftCommon Stock | 6,291 | $0.00 | $0.00 |
DisclosureSEC source: 0001993684-26-000002 · form4-04012026_090411.xml · nonDerivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,438 Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 12:43 UTC | Immunome Inc. IMNM · Entity 4219 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001993684-25-000004 · form4-12222025_121242.xml · nonDerivative · entry 6 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for Child 3 Disclosed balance after: 1,000 F1 · kind: Reflects the gift of shares by the Reporting Person to a custodial account for the child of the Reporting Person established pursuant to the Uniform Transfer to Minors Act, for which the Reporting Person serves as a custodian. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. F2 · shares: The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025 (the "Lock-up Agreement"). The transferee has agreed to be bound by the terms of the Lock-up Agreement. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 12:43 UTC | Immunome Inc. IMNM · Entity 4219 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001993684-25-000004 · form4-12222025_121242.xml · nonDerivative · entry 5 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,729 F1 · kind: Reflects the gift of shares by the Reporting Person to a custodial account for the child of the Reporting Person established pursuant to the Uniform Transfer to Minors Act, for which the Reporting Person serves as a custodian. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 12:43 UTC | Immunome Inc. IMNM · Entity 4219 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001993684-25-000004 · form4-12222025_121242.xml · nonDerivative · entry 4 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for Child 2 Disclosed balance after: 1,000 F1 · kind: Reflects the gift of shares by the Reporting Person to a custodial account for the child of the Reporting Person established pursuant to the Uniform Transfer to Minors Act, for which the Reporting Person serves as a custodian. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. F2 · shares: The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025 (the "Lock-up Agreement"). The transferee has agreed to be bound by the terms of the Lock-up Agreement. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 12:43 UTC | Immunome Inc. IMNM · Entity 4219 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001993684-25-000004 · form4-12222025_121242.xml · nonDerivative · entry 3 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,729 F1 · kind: Reflects the gift of shares by the Reporting Person to a custodial account for the child of the Reporting Person established pursuant to the Uniform Transfer to Minors Act, for which the Reporting Person serves as a custodian. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 12:43 UTC | Immunome Inc. IMNM · Entity 4219 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001993684-25-000004 · form4-12222025_121242.xml · nonDerivative · entry 2 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Indirect · As Custodian for Child 1 Disclosed balance after: 1,000 F1 · kind: Reflects the gift of shares by the Reporting Person to a custodial account for the child of the Reporting Person established pursuant to the Uniform Transfer to Minors Act, for which the Reporting Person serves as a custodian. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. F2 · shares: The shares are subject to a lockup agreement entered into by the Reporting Person on December 15, 2025 (the "Lock-up Agreement"). The transferee has agreed to be bound by the terms of the Lock-up Agreement. Read SEC document |
| December 19, 2025 Filed Dec 22, 2025 12:43 UTC | Immunome Inc. IMNM · Entity 4219 | GiftCommon Stock | 1,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001993684-25-000004 · form4-12222025_121242.xml · nonDerivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,729 F1 · kind: Reflects the gift of shares by the Reporting Person to a custodial account for the child of the Reporting Person established pursuant to the Uniform Transfer to Minors Act, for which the Reporting Person serves as a custodian. The Reporting Person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such shares for purposes of Section 16 or for any other purpose. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 01:04 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionEmployee Stock option (right to buy) · Derivative | 22,000 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001415889-25-024319 · form4-09122025_010912.xml · derivative · entry 2 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,840 Underlying: Common Stock · 22,000 shares Expires 2032-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vested on May 1, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| September 10, 2025 Filed Sep 12, 2025 01:04 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 22,000 | $1.35 | $29,700.00 |
DisclosureSEC source: 0001415889-25-024319 · form4-09122025_010912.xml · nonDerivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 29, 2025 Filed Jul 31, 2025 22:52 UTC | Immunome Inc. IMNM · Entity 4219 | GrantEmployee Stock Option (right to buy) · Derivative | 196,000 | $0.00 Strike: $10.60 | $0.00 |
DisclosureSEC source: 0001415889-25-020784 · form4-07312025_100740.xml · derivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196,000 Underlying: Common Stock · 196,000 shares Expires 2035-07-28 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on July 29, 2026, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| March 27, 2025 Filed Mar 28, 2025 21:54 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionEmployee Stock option (right to buy) · Derivative | 5,200 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001415889-25-009201 · form4-03282025_090359.xml · derivative · entry 2 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 173,840 Underlying: Common Stock · 5,200 shares Expires 2032-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares vested on May 1, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| March 27, 2025 Filed Mar 28, 2025 21:54 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 5,200 | $1.35 | $7,020.00 |
DisclosureSEC source: 0001415889-25-009201 · form4-03282025_090359.xml · nonDerivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,729 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2024 Filed Aug 20, 2024 01:05 UTC | Immunome Inc. IMNM · Entity 4219 | GiftCommon Stock | 2,471 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-021656 · form4-08202024_010805.xml · nonDerivative · entry 3 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,529 Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 01:05 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionStock option (right to buy) · Derivative | 19,524 | $0.00 Strike: $1.35 | $0.00 |
DisclosureSEC source: 0001415889-24-021656 · form4-08202024_010805.xml · derivative · entry 4 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 179,040 Underlying: Common Stock · 19,524 shares Expires 2032-06-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares vested on May 1, 2023, and the remaining shares shall vest in 36 equal monthly installments thereafter. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 01:05 UTC | Immunome Inc. IMNM · Entity 4219 | SaleCommon Stock | 3,524 | $13.93 | $49,071.70 |
DisclosureSEC source: 0001415889-24-021656 · form4-08202024_010805.xml · nonDerivative · entry 2 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The shares were sold pursuant to sell to cover transactions. F2 · price: The weighted average sale price for the transaction report was $13.925, and the range of prices were between $13.800 and $14.020. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 15, 2024 Filed Aug 20, 2024 01:05 UTC | Immunome Inc. IMNM · Entity 4219 | Exercise / conversionCommon Stock | 19,524 | $1.35 | $26,357.40 |
DisclosureSEC source: 0001415889-24-021656 · form4-08202024_010805.xml · nonDerivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,524 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 09, 2024 Filed Aug 13, 2024 21:36 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 190,000 | $0.00 Strike: $12.92 | $0.00 |
DisclosureSEC source: 0001415889-24-021226 · form4-08132024_090822.xml · derivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2034-08-08 F1 · derivative.exercise_date: 25% of the shares subject to the options vest on August 9, 2025, and one-thirty-sixth (1/36th) of the remaining shares subject to the options shall vest every month thereafter. Read SEC document |
| December 01, 2023 Filed Dec 6, 2023 02:08 UTC | Immunome Inc. IMNM · Entity 4219 | GrantStock option (right to buy) · Derivative | 200,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001209191-23-057567 · doc4.xml · derivative · entry 1 Higgins Jack · CIK 0001993684 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2033-11-30 F1 · derivative.exercise_date: On December 1, 2023, Dr. Higgins was granted an option to purchase 200,000 shares of common stock. The option vests (i) with respect to 100,000 shares, 25% of such shares subject to the option, vest on November 17, 2024, and the remaining shares will vest monthly thereafter over three years, and (ii) with respect to the remaining 100,000 shares, which vesting shall commence as of the date a certain condition set forth in Dr. Higgins' Amended and Restated Offer Letter dated November 30, 2023, is satisfied, 25% of the shares subject to the option will vest 1 year from the completion of that certain condition, and the remaining shares will vest monthly thereafter over three years. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.